Researchers have determined the optimal preoperative radiation dose for patients with resectable sinonasal squamous cell carcinoma (SNSCC), according to a poster presented at the ASTRO 67th Annual Meeting.
“Preoperative radiotherapy has demonstrated promising results in organ preservation and therapeutic effectiveness for patients with resectable SNSCC,” the researchers wrote in their abstract. “However, the optimal radiation dose remains undefined.”
In their study, the researchers included 96 patients with resectable SNSCC who received preoperative radiotherapy. Patients were grouped according to dose: less than 60 Gy, 60–62 Gy, and greater than 62 Gy.
With a median follow-up time of 135.06 months, the hazard ratio curve showed that 60-62 Gy was the optimal dose range. The 5-year overall survival (OS) was 72.1% in this optimal-dose group compared with 44.6% in the low-dose group and 52.3% in the high-dose group.
In addition, the data showed that patients who received the higher dose had increased perioperative complications and late toxicities, with no additional survival benefits.
The researchers also conducted a multivariate analysis, which showed that OS was associated with age, T stage, and radiation dose.
